Welcome to the New York Stock Exchange, where Johnson & Johnson (NYSE: JNJ) is taking the stage. Big pharmaceutical companies like Bristol Myers Squibb, Merck, and Johnson & Johnson are facing a significant threat as blockbuster drugs are set to lose patent protection, potentially putting billions of dollars in sales at risk by 2030. This patent cliff occurs when a company’s patents for leading branded products expire, allowing competitors to sell generic versions at lower prices. While this may reduce revenue for drugmakers, it can benefit patients by providing more affordable options. Despite these challenges, some drugmakers are proactively addressing the issue by developing new drugs and forming strategic partnerships. The pharmaceutical industry must continually innovate to replace best-selling drugs with new, innovative treatments. For more information, visit www.cnbc.com on 2024-01-28 08:00:01.
